Rilpivirine

Cat. No.: A3765
CAS No.: 500287-72-9
Formula: C22H18N6
M.Wt: 366.42

Synonyms:
- R 278474;TMC 278;R 278474;R278474;TMC278;TMC-278

Target: Microbiology & Virology
Pathway: HIV
Storage: Store at -20°C

Solvent & Solubility

In Vitro

Preparing
Stock Solutions

<table>
<thead>
<tr>
<th>Mass</th>
<th>1mg</th>
<th>5mg</th>
<th>10mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.7291 mL</td>
<td>13.6455 mL</td>
<td>27.2911 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.5458 mL</td>
<td>2.7291 mL</td>
<td>5.4582 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2729 mL</td>
<td>1.3646 mL</td>
<td>2.7291 mL</td>
</tr>
</tbody>
</table>

≥12.25 mg/mL in DMSO, ≥6.58 mg/mL in EtOH with ultrasonic and warming, insoluble in H2O

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Short summary
Inhibitor of next-generation nonnucleoside reverse transcriptase

IC50 & Target

Cell Viability Assay

In Vitro

Cell Line: Caco-2 cell lines
Preparation method: The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions: 1 h; 20 μM
Applications: The ability of rilpivirine to inhibit ABCB1-mediated transport of digoxin was assessed using Caco-2 cell monolayers. Permeation of 1 μM digoxin in the A-to-B direction was significantly increased when it was coincubated with rilpivirine at 1 μM, 3μM, 10μM and 30μM compared with that for the rilpivirine-free controls. Permeation of 1 μM digoxin in the B-to-A direction was significantly decreased when it was coincubated with 10 μM rilpivirine and 30 μM rilpivirine compared with rilpivirine-free control incubations.

Animal models: Six male beagle dogs

Dosage form: Per dog, two vials each containing 25 mg of TMC278; oral taken

In dogs, TMC278 (rilpivirine) was more slowly absorbed from tablets than from the suspended powders for reconstitution. Compared to the tablet, the relative bioavailability obtained with the powders ranged between 69% and 89% for TMC278/PVP-VA 64 1:9 (w/w) and between 85% and 157% for TMC278/PVP-VA 64/Cremophor EL 1:8.5:0:5 (w/w/w).

Other notes: Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.


References


Caution

FOR RESEARCH PURPOSES ONLY.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.